Header Logo

Connection

JAMES C YAO to Treatment Outcome

Back to Details
This is a "connection" page, showing publications JAMES C YAO has written about Treatment Outcome.
JAMES C YAO
Connection Strength
0.654
Treatment Outcome
  1. Assessment of Clinical Response Following Atezolizumab and Bevacizumab Treatment in Patients With Neuroendocrine Tumors: A Nonrandomized Clinical Trial. JAMA Oncol. 2022 06 01; 8(6):904-909.
    View in: PubMed
    Score: 0.046
  2. Relationship between metabolic toxicity and efficacy of everolimus in patients with neuroendocrine tumors: A pooled analysis from the randomized, phase 3 RADIANT-3 and RADIANT-4 trials. Cancer. 2021 Aug 01; 127(15):2674-2682.
    View in: PubMed
    Score: 0.042
  3. Recurrence of Metastatic Pro-insulinoma Nearly 50?Years After Subtotal Pancreatectomy. J Gastrointest Cancer. 2019 Jun; 50(2):345-348.
    View in: PubMed
    Score: 0.037
  4. Octreotide LAR Dosage and Survival Among Elderly Patients With Distant-Stage Neuroendocrine Tumors. Oncologist. 2016 Mar; 21(3):308-13.
    View in: PubMed
    Score: 0.030
  5. [177Lu-DOTA0,Tyr3]-octreotate in the treatment of midgut neuroendocrine tumors. Future Oncol. 2016 Feb; 12(3):313-21.
    View in: PubMed
    Score: 0.030
  6. Everolimus for the treatment of advanced, non-functional neuroendocrine tumours of the lung or gastrointestinal tract (RADIANT-4): a randomised, placebo-controlled, phase 3 study. Lancet. 2016 Mar 05; 387(10022):968-977.
    View in: PubMed
    Score: 0.029
  7. Perfusion computed tomography as functional biomarker in randomized run-in study of bevacizumab and everolimus in well-differentiated neuroendocrine tumors. Pancreas. 2015 Mar; 44(2):190-7.
    View in: PubMed
    Score: 0.028
  8. Impact of prior chemotherapy use on the efficacy of everolimus in patients with advanced pancreatic neuroendocrine tumors: a subgroup analysis of the phase III RADIANT-3 trial. Pancreas. 2015 Mar; 44(2):181-9.
    View in: PubMed
    Score: 0.028
  9. Octreotide long-acting repeatable use among elderly patients with carcinoid syndrome and survival outcomes: a population-based analysis. Cancer. 2014 Jul 01; 120(13):2039-49.
    View in: PubMed
    Score: 0.026
  10. A rationale for multidisciplinary care in treating neuroendocrine tumours. Curr Opin Endocrinol Diabetes Obes. 2012 Aug; 19(4):306-13.
    View in: PubMed
    Score: 0.023
  11. Chromogranin A and neuron-specific enolase as prognostic markers in patients with advanced pNET treated with everolimus. J Clin Endocrinol Metab. 2011 Dec; 96(12):3741-9.
    View in: PubMed
    Score: 0.022
  12. Future directions in the treatment of neuroendocrine tumors: consensus report of the National Cancer Institute Neuroendocrine Tumor clinical trials planning meeting. J Clin Oncol. 2011 Mar 01; 29(7):934-43.
    View in: PubMed
    Score: 0.021
  13. Octreotide LAR in carcinoid: how to dose? Pancreas. 2008 Oct; 37(3):337-8; author reply 338-9.
    View in: PubMed
    Score: 0.018
  14. Yttrium-90 microsphere radioembolotherapy of hepatic metastatic neuroendocrine carcinomas after hepatic arterial embolization. J Vasc Interv Radiol. 2008 Jan; 19(1):145-51.
    View in: PubMed
    Score: 0.017
  15. Clinical and in vitro studies of imatinib in advanced carcinoid tumors. Clin Cancer Res. 2007 Jan 01; 13(1):234-40.
    View in: PubMed
    Score: 0.016
  16. Update on the management of neuroendocrine hepatic metastases. J Vasc Interv Radiol. 2006 Aug; 17(8):1235-49; quiz 1250.
    View in: PubMed
    Score: 0.015
  17. Fluorouracil, doxorubicin, and streptozocin in the treatment of patients with locally advanced and metastatic pancreatic endocrine carcinomas. J Clin Oncol. 2004 Dec 01; 22(23):4762-71.
    View in: PubMed
    Score: 0.014
  18. Association between expression of transcription factor Sp1 and increased vascular endothelial growth factor expression, advanced stage, and poor survival in patients with resected gastric cancer. Clin Cancer Res. 2004 Jun 15; 10(12 Pt 1):4109-17.
    View in: PubMed
    Score: 0.013
  19. Randomized Study of Temozolomide or Temozolomide and Capecitabine in Patients With Advanced Pancreatic Neuroendocrine Tumors (ECOG-ACRIN E2211). J Clin Oncol. 2023 03 01; 41(7):1359-1369.
    View in: PubMed
    Score: 0.012
  20. Therapy of localized gastric cancer: preoperative and postoperative approaches. Ann Oncol. 2002; 13 Suppl 4:7-12.
    View in: PubMed
    Score: 0.011
  21. Fluorouracil, Doxorubicin with Streptozocin and Subsequent Therapies in Pancreatic Neuroendocrine Tumors. Neuroendocrinology. 2022; 112(1):34-42.
    View in: PubMed
    Score: 0.010
  22. Impact of liver tumour burden, alkaline phosphatase elevation, and target lesion size on treatment outcomes with 177Lu-Dotatate: an analysis of the NETTER-1 study. Eur J Nucl Med Mol Imaging. 2020 09; 47(10):2372-2382.
    View in: PubMed
    Score: 0.010
  23. Phase I studies of vorinostat with ixazomib or pazopanib imply a role of antiangiogenesis-based therapy for TP53 mutant malignancies. Sci Rep. 2020 02 20; 10(1):3080.
    View in: PubMed
    Score: 0.010
  24. Everolimus in advanced, progressive, well-differentiated, non-functional neuroendocrine tumors: RADIANT-4 lung subgroup analysis. Cancer Sci. 2018 Jan; 109(1):174-181.
    View in: PubMed
    Score: 0.008
  25. Health-related quality of life for everolimus versus placebo in patients with advanced, non-functional, well-differentiated gastrointestinal or lung neuroendocrine tumours (RADIANT-4): a multicentre, randomised, double-blind, placebo-controlled, phase 3 trial. Lancet Oncol. 2017 10; 18(10):1411-1422.
    View in: PubMed
    Score: 0.008
  26. Natural History of T1N0M0 Hepatocellular Carcinoma: Large-Scale Study in the United States. Oncology. 2017; 93(4):233-242.
    View in: PubMed
    Score: 0.008
  27. The North American Neuroendocrine Tumor Society Consensus Guidelines for Surveillance and Medical Management of Midgut Neuroendocrine Tumors. Pancreas. 2017 07; 46(6):707-714.
    View in: PubMed
    Score: 0.008
  28. Everolimus Effect on Gastrin and Glucagon in Pancreatic Neuroendocrine Tumors. Pancreas. 2017 07; 46(6):751-757.
    View in: PubMed
    Score: 0.008
  29. Everolimus in Neuroendocrine Tumors of the Gastrointestinal Tract and Unknown Primary. Neuroendocrinology. 2018; 106(3):211-220.
    View in: PubMed
    Score: 0.008
  30. Antiangiogenesis and gene aberration-related therapy may improve overall survival in patients with concurrent KRAS and TP53 hotspot mutant cancer. Oncotarget. 2017 May 16; 8(20):33796-33806.
    View in: PubMed
    Score: 0.008
  31. Loss of DPC4/SMAD4 expression in primary gastrointestinal neuroendocrine tumors is associated with cancer-related death after resection. Surgery. 2017 03; 161(3):753-759.
    View in: PubMed
    Score: 0.008
  32. Efficacy of octreotide long-acting repeatable in neuroendocrine tumors: RADIANT-2 placebo arm post hoc analysis. Endocr Relat Cancer. 2015 Dec; 22(6):933-40.
    View in: PubMed
    Score: 0.007
  33. From Protocols to Publications: A Study in Selective Reporting of Outcomes in Randomized Trials in Oncology. J Clin Oncol. 2015 Nov 01; 33(31):3583-90.
    View in: PubMed
    Score: 0.007
  34. Pazopanib and depot octreotide in advanced, well-differentiated neuroendocrine tumours: a multicentre, single-group, phase 2 study. Lancet Oncol. 2015 Jun; 16(6):695-703.
    View in: PubMed
    Score: 0.007
  35. Impact of Previous Somatostatin Analogue Use on the Activity of Everolimus in Patients with Advanced Neuroendocrine Tumors: Analysis from the Phase III RADIANT-2 Trial. Neuroendocrinology. 2015; 102(1-2):18-25.
    View in: PubMed
    Score: 0.007
  36. A phase I study of imatinib, dacarbazine, and capecitabine in advanced endocrine cancers. BMC Cancer. 2014 Aug 02; 14:561.
    View in: PubMed
    Score: 0.007
  37. Telotristat etiprate, a novel serotonin synthesis inhibitor, in patients with carcinoid syndrome and diarrhea not adequately controlled by octreotide. Endocr Relat Cancer. 2014 Oct; 21(5):705-14.
    View in: PubMed
    Score: 0.007
  38. Resection of at-risk mesenteric lymph nodes is associated with improved survival in patients with small bowel neuroendocrine tumors. World J Surg. 2013 Jul; 37(7):1695-700.
    View in: PubMed
    Score: 0.006
  39. Attempted salvage resection for recurrent gastric or gastroesophageal cancer. Ann Surg Oncol. 2009 Jan; 16(1):42-50.
    View in: PubMed
    Score: 0.004
  40. A phase II study of pegylated-camptothecin (pegamotecan) in the treatment of locally advanced and metastatic gastric and gastro-oesophageal junction adenocarcinoma. Cancer Chemother Pharmacol. 2009 Jan; 63(2):363-70.
    View in: PubMed
    Score: 0.004
  41. Management of pancreatic endocrine tumors in multiple endocrine neoplasia type 1. World J Surg. 2006 May; 30(5):643-53.
    View in: PubMed
    Score: 0.004
  42. Multicenter phase II trial of S-1 plus cisplatin in patients with untreated advanced gastric or gastroesophageal junction adenocarcinoma. J Clin Oncol. 2006 Feb 01; 24(4):663-7.
    View in: PubMed
    Score: 0.004
  43. Carcinoid tumors of the duodenum. Surgery. 2005 Dec; 138(6):971-7; discussion 977-8.
    View in: PubMed
    Score: 0.004
  44. Phase I pharmacokinetic study of S-1 plus cisplatin in patients with advanced gastric carcinoma. J Clin Oncol. 2005 Oct 01; 23(28):6957-65.
    View in: PubMed
    Score: 0.004
  45. Induction chemotherapy improved outcomes of patients with resectable esophageal cancer who received chemoradiotherapy followed by surgery. Int J Radiat Oncol Biol Phys. 2004 Oct 01; 60(2):427-36.
    View in: PubMed
    Score: 0.003
  46. Endoscopic ultrasound after preoperative chemoradiation can help identify patients who benefit maximally after surgical esophageal resection. Am J Gastroenterol. 2004 Jul; 99(7):1258-66.
    View in: PubMed
    Score: 0.003
  47. Hepatic artery embolization and chemoembolization for treatment of patients with metastatic carcinoid tumors: the M.D. Anderson experience. Cancer J. 2003 Jul-Aug; 9(4):261-7.
    View in: PubMed
    Score: 0.003
Connection Strength

The connection strength for concepts is the sum of the scores for each matching publication.

Publication scores are based on many factors, including how long ago they were written and whether the person is a first or senior author.